IFN-α in Relapse Prevention.

To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

NCT Number	NCT07449286
Lead Sponsor	Peking University People's Hospital Collaborators: Aerospace Medical Center, LU DAOPEI MEDICAL, Nanfang Hospital, Southern Medical University, Zhejiang University
Conditions	Acute Myeloid Leukemia, Myelodysplastic Syndromes
Enrollment	100 participants
Start Date	2026-03-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-04